A practical guide for Phase 3 biotech on building a right-sized pharmacovigilance system before EU approval — what to build, when, and how to avoid over- or under-investing.
Understand the difference between PSUR, PBRER, and DSUR — which periodic safety report applies, when, and what changes for biotech moving from Phase 3 to marketing.
Learn how to select the right EU QPPV provider for your biotech. Compare costs, evaluate key criteria, and avoid common mistakes in pharmacovigilance outsourcing.